Recent advances in the immunodiagnosis of epithelial ovarian carcinoma

  • Robert C. BastJr.
  • Robert C. Knapp
Part of the Cancer Treatment and Research book series (CTAR, volume 23)


Since we last reviewed the immunology of ovarian carcinoma for this series [1], there have been several advances in the development of serum markers for epithelial ovarian cancer. Much of this progress has related to the identification of tumor associated antigens using the monoclonal technology [2].


Ovarian Cancer Ovarian Carcinoma Epithelial Ovarian Cancer Ovarian Tumor Ovarian Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bast RC Jr, Knapp RC: The immunobiology of ovarian carcinoma. In: Gynecologic Oncology, Griffiths CT, Fuller AF (eds). Boston: Martinus Nijhoff Publishers, 1983, pp 187–226.Google Scholar
  2. 2.
    Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497, 1975.PubMedCrossRefGoogle Scholar
  3. 3.
    Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337, 1981.PubMedCrossRefGoogle Scholar
  4. 4.
    Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB: Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC 125. Int J Gyn Path 2:275–285, 1983.CrossRefGoogle Scholar
  5. 5.
    Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Colvin RB: Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am J Clin Path 79:98–104, 1983.PubMedGoogle Scholar
  6. 6.
    Buick RN, Pullano R, Knapp RC, Urbach GI, Chang PL, Bast RC Jr: Classification of ovarian tumor associated antigens on the basis of distribution on cell populations undergoing differentiation. Proc Amer Assoc Cancer Res 25:40, (abstr), 1984.Google Scholar
  7. 7.
    Masuho Y, Zalutsky M, Knapp RC, Bast RC Jr: Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res, 44:2813–2819, 1984.PubMedGoogle Scholar
  8. 8.
    Bast RC Jr, Klug TL, St. John E, Jenison E, Niloff J, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887, 1983.PubMedCrossRefGoogle Scholar
  9. 9.
    Klug TL, Bast RC Jr, Niloff JM, Knapp RC, Zurawski VR Jr: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 44:1048–1053, 1984.PubMedGoogle Scholar
  10. 10.
    Bast RC Jr, Klug TL, Schaetzl E, Lavin P, Niloff J, Greber TF, Zurawski VR Jr, Knapp RC: Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9 and carcinoembryonic antigen, Am J Obstet Gynecol, 149:553–559, 1984.PubMedGoogle Scholar
  11. 11.
    Chatal JF, Ricolleau G, Fumoleau P, Kramer M, Curtet C, Douillard JY: Radioimmunoassay of the CA 12-5 antigen in epithelial ovarian carcinomas. Cancer Detection Prevention 6:624, 1983.Google Scholar
  12. 12.
    Crombach G, Zippel HH, Wurz H: Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer. Cancer Detection Prevention 6:623, 1983.Google Scholar
  13. 13.
    Kreienberg R, Melchart: CA 125-A new radioimmunoassay for monitoring patients with epithelial ovarian carcinoma. Cancer Detection Prevention 6:619, 1983.Google Scholar
  14. 14.
    Niloff JM, Klug TL, Schaetzl E, Zurawski VR Jr, Knapp RC, Bast RC JR: Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol, 148:1057–1058, 1984.PubMedGoogle Scholar
  15. 15.
    Bast RC Jr, Siegal EP, Runowicz C, Klug TL, Zurawski VR Jr, Schonoholz D, Cohen CJ, Knapp RC: Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol, in press.Google Scholar
  16. 16.
    Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC Jr: Ca 125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol, in press.Google Scholar
  17. 17.
    Ruibal A, Encabo G, Miralles EM, Domenech FM: CA 125 seric levels in non ovarian pathologies. Med Clin (Barcelona) 82:500–501, 1984.Google Scholar
  18. 18.
    Bhattacharya M, Chatterjee SK, Barlow JJ, Fuji H: Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas. Cancer Res 42:1650–1654, 1982.PubMedGoogle Scholar
  19. 19.
    Colnaghi MI, Canaveri S, Dellatorre G, et al.: Monoclonal antibodies directed against human tumors. Proc 13th Int Cancer Congress P. 55, 1982.Google Scholar
  20. 20.
    Berkowitz RS, Kabawat S, Lazarus H, Colvin RC, Knapp RC, Bast RC Jr: Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. Am J Obstet Gynecol 146:607–612, 1983.PubMedGoogle Scholar
  21. 21.
    Mattes MJ, Cordon-Cardo C, Lewis JC Jr, et al.: Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. Proc Natl Acad Sci (USA), in press.Google Scholar
  22. 22.
    Metzgar RS, Gaillard MT, Levske JJ, et al.: Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res 42:601–608, 1982.PubMedGoogle Scholar
  23. 23.
    Metzgar RS, Rodriguez BS, Daasch VN, Fernsten PD, Meyers WC, Sindelar WF, Sandler RS, Seigler HF: Competition radioimmune assay for detection of a pancreatic cancer associated antigen (DU-PAN-2) in serum and ascited of patients with adenocarcinoma. Proc Natl Acad Sci (USA), in press.Google Scholar
  24. 24.
    Daasch VN, Fernsten PD, Metzgar RS: Radioimmunoassay studies of a monoclonal antibody to detect antigen (DUPAN-2) in the serum or ascites of adenocarcinoma patients. Proc Amer Assoc Cancer Res 23:266, 1982.Google Scholar
  25. 25.
    Papsidero LD, Croghan GA, O’Connell MJ, Valenzuela LA, Nemoto T, Chu TM: Monoclonal antibodies (F36/22 and M7/105) to human breast carcinoma. Cancer Res 43:1741–1747, 1983.PubMedGoogle Scholar
  26. 26.
    Croghan GA, Papsidero LD, Valenzuela LA, Nemoto T, Penetrante R, Chu TM: Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22. Cancer Res 43:4980–4988, 1983.PubMedGoogle Scholar
  27. 27.
    Croghan GA, Wingate MB, Gamarra M, Johnson E, Chu TM, Allen H, Valenzuela L, Tsukada Y, Papsidero D: Reactivity of monoclonal antibody F36/22 with human ovarian adenocarcinomas. Cancer Res 44:1954–1962, 1984.PubMedGoogle Scholar
  28. 28.
    Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer JP: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957–972, 1979.PubMedCrossRefGoogle Scholar
  29. 29.
    Magnani JL, Steplewski Z, Koprowski H, Ginsburg V: Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 43:5489–5492, 1983.PubMedGoogle Scholar
  30. 30.
    Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rake B, Space S, Westrick B, Schoemaker H, Zurawski VR Jr: Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clinical Chem. 29/3:549–552, 1983.Google Scholar
  31. 31.
    Herlyn M, Sears HF, Steplewski Z, Koprowski H: Monoclonal antibody detection of a circulating tumor-associated antigen I. Presence of antigen in sera of patients with colorectal, gastric and pancreatic carcinoma. J Clin Immunol 2:135–140, 1982.PubMedCrossRefGoogle Scholar
  32. 32.
    Charpin C, Bhan AK, Zurawski VR Jr, Scully RE: Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: An immunohistochemical study with the use of monoclonal antibodies. Int J Gynecol Path 1:231–245, 1982.CrossRefGoogle Scholar
  33. 33.
    Bast RC Jr, Klug T, Knapp RC, Zurawski VR Jr: CA 125 and CA 19-9 can be expressed on the same mucin-like glycoprotein. Submitted for publication.Google Scholar
  34. 34.
    Chatterjee SK, Bhattacharya M, Barlow J: Glycosyltransferase and glycosidase activities in ovarian cancer patients. Cancer Res 39:1943–1951, 1979.PubMedGoogle Scholar
  35. 35.
    Waalkes TP, Rosenshein NB, Shaper JH, Ettinger DS, Woo KB, Paone JF, Gehrke CW: A feasibility study in the development of biological markers for ovarian cancer. J. Surgical Onc 21:207–214, 1982.CrossRefGoogle Scholar
  36. 36.
    Gauduchon P, Tillier C, Guyonnet C, Heron JF, Bar-Guilloux E, Talaer JY: Clinical value of serum glycoprotein galactosyltransferase levels in different histological types of ovarian carcinoma. Cancer Res 43:4491–4496, 1983.PubMedGoogle Scholar
  37. 37.
    Chatterjee SK, Chowdhury K, Bhattacharya M, Barlow J: Beta-hexosaminidase activities and isoenzymes in normal human ovary and ovarian adenocarcinoma. Cancer 49:128–135, 1982.PubMedCrossRefGoogle Scholar
  38. 38.
    Barlow JJ, DiCioccio RA, Dillard PH, Blumenson LE, Matta KL: Frequency of an allele for low activity of -L-Fucosidase in sera: Possible increase in epithelial ovarian cancer patients. JNCI 67:1005–1009, 1981.PubMedGoogle Scholar
  39. 39.
    Barlow JJ, Dillard PH: Serum protein-bound fucose in patients with gynecologic cancers. Obstet Gynecol 39:727–733, 1972.PubMedGoogle Scholar
  40. 40.
    Atkin NB, Baker MC, Robinson R, Gaze SE: Chromosome studies on 14 near-diploid carcinomas of the ovary. Eur J Cancer 10:143–146, 1972.Google Scholar
  41. 41.
    Kakati S, Hayata I, Oshimure M, Sandberg AA: Chromosomes and causation of human cancer and leukemia. X. banding patterns in cancerous effusions. Cancer 35:1729–1738, 1975.CrossRefGoogle Scholar
  42. 42.
    Trent JM, Salmon SE: Karyotypic analysis of human ovarian carcinoma cells cloned in agar. Am J Human Genet 31:379 (abstr), 1979.Google Scholar
  43. 43.
    Whang-Peng J, Knutsen T, Douglass EC, Chu E, Ozols RF, Hogan WM, Young RC: Cytogenetic studies in ovarian cancer. Cancer Genetics and Cytogenetics 11:91–106, 1984.PubMedCrossRefGoogle Scholar
  44. 44.
    Feig L, Bast RC Jr, Knapp RC, Cooper GM: Somatic activation of rask gene in a human ovarian carcinoma. Science 223:698–701, 1984.PubMedCrossRefGoogle Scholar
  45. 45.
    Slamon DJ, deKernoin J, Verma IM, Cline M: Expression of cellular oncogenes in human malignancies. Science 224:256–252, 1984.PubMedCrossRefGoogle Scholar
  46. 46.
    Knauf S, Urbach GI: A study of ovarian cancer patients using a radioimmunoassay for human ovarian tumor associated antigen OCA.Am J Obstet Gynecol 138:1222, 1223, 1980.PubMedGoogle Scholar
  47. 47.
    Bhattacharya M, Barlow JJ: Ovarian cystadenocarcinoma-associated antigen (OCAA). In: Compendium of Assays for Immunodiagnosis of Human Cancer. Herberman RB (ed). Amsterdam: Elsevier, North Holland Inc, pp 527–431, 1979.Google Scholar
  48. 48.
    Knauf S, Urbach GI: Identification, purification and radioimmunoassay of NB/70K, a human ovarian tumor-associated antigen. Cancer Res 41:1351–1357, 1981.PubMedGoogle Scholar
  49. 49.
    Chang P-L, Urbach GI, Dembo AJ: Circulating levels of ovarian cancer antigen NB/70K: Clinical correlations. Proc Amer Soc Clin Oncol 3:2, 1984.Google Scholar
  50. 50.
    Knauf S, Taillon-Miller P, Helmkamp F, Bonfiglio TA, Beecham JB: Selectivity for ovarian cancer of an improved serum radioimmunoassay for human ovarian tumor-associated antigen NB/70K. Gynecologic Oncol 17:349–355, 1984.CrossRefGoogle Scholar
  51. 51.
    Woods JC, Sprigas AI, Harris H, McGee JO’D: A new marker for human cancer cells. 3. Immunocytochemical detection of malignant cells in serous fluids with the Ca-1 antibody. Lancet 2:512–514, 1982.PubMedCrossRefGoogle Scholar
  52. 52.
    Epenetos AA, Canti G, Taylor-Papadimitriou J, Curling M, Bodmer WF: Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions. Lancet 2:1004–1006, 1982.PubMedCrossRefGoogle Scholar
  53. 53.
    Bramwell ME, Bhavanadant VP, Wiseman G, Harris H: Structure and function of the Ca antigen. Br J Cancer 48:177–183, 1983.PubMedCrossRefGoogle Scholar
  54. 54.
    Van Nagell JR Jr, Kim E, Casper S, et al.: Radioimmunodetection of primary and metastatic ovarian cancer using radiolabeled antibodies to carcinoembryonic antigen. Cancer Res 40:502–506, 1980.PubMedGoogle Scholar
  55. 55.
    Epenetos AA, Britton KE, Mather S, Shepherd J, Granowska M, Taylor-Papadimitriou J, Nimmon CC, Durbin H, Hawkins LR, Malpas JS: Targeting of iodine-123 labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet 2:999–1004, 1982.PubMedCrossRefGoogle Scholar
  56. 56.
    Shephard JH, Epenetos AA, Britton KE, et al.: Radioimmune diagnosis of ovarian carcinoma using tumor associated monoclonal antibodies. Proc Soc Gyn Oncol 14:12, 1983.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • Robert C. BastJr.
  • Robert C. Knapp

There are no affiliations available

Personalised recommendations